

**Cost-effectiveness of golimumab (Simponi®) in the treatment of  
moderate to severe rheumatoid arthritis**



June 2010

## Summary

1. Our initial review completed in May 2010 concluded that golimumab was not cost-effective for the treatment of moderate to severe rheumatoid arthritis in the Irish Healthcare setting. On the 12<sup>th</sup> May 2010 the price of golimumab was revised.
2. Following the price reduction the ICER for golimumab plus MTX versus MTX alone was estimated at €6,727/QALY. Probabilistic sensitivity analysis (PSA) indicated that the probability of golimumab being cost-effective as being compared with the other anti-TNF drugs at the €20,000/QALY threshold increased to 23%.
3. Following the price review we believe golimumab (Simponi®) to be a cost-effective option for the treatment of rheumatoid arthritis in patients who failed MTX. The cost-effectiveness of golimumab was similar to other available anti-TNF agents. We are happy to recommend reimbursement of golimumab at the revised price.